The Evolving Patient Profile in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this opening segment, Dr. Charles J. Ryan introduces the discussion and frames the evolving treatment landscape of metastatic castration sensitive prostate cancer (mCSPC). He invites Dr. Alan H. Bryce to describe how the typical patient with mCSPC seen in clinical practice today differs from those treated a decade ago. Dr. Bryce highlights that many patients are now living significantly longer with metastatic disease due to earlier diagnosis, improved systemic therapies, and broader adoption of treatment intensification strategies. As a result, clinicians are increasingly managing an aging population with multiple comorbidities such as cardiovascular disease, diabetes, and metabolic disorders, often accompanied by polypharmacy. The conversation emphasizes that these patients may remain on therapy for years, making long term tolerability and quality of life critical considerations in treatment planning. The segment sets the stage for the program by underscoring how changes in patient demographics and survivorship expectations are shaping modern management strategies in mCSPC.